HRMY NASDAQ
Harmony Biosciences Holdings, Inc.
1W: -1.9%
1M: -5.2%
3M: +5.8%
YTD: +1.5%
1Y: +25.4%
3Y: +88.5%
5Y: -9.4%
$37.95
+1.12 (+3.04%)
Weekly Expected Move ±5.1%
$32
$34
$36
$38
$40
Credit Risk of going bust: lower than 74% of companies Debt: 6.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.26 (down 99.3%), Harmony Biosciences Holdings, Inc. would be worth roughly what it owes.
Total debt $154.0M against a stock market value of $2.21B.
Distance to default 8.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $87.0M (short-term plus half of long-term), stock volatility 40.3%; Altman Z'' 7.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.26 (down 99.3%), Harmony Biosciences Holdings, Inc. would be worth roughly what it owes.
Total debt $154.0M against a stock market value of $2.21B.
Distance to default 8.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $87.0M (short-term plus half of long-term), stock volatility 40.3%; Altman Z'' 7.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.09
Neutral
4 bullish
3 neutral
3 bearish
Articles (7d)
10
Daily Sentiment (7 Days)
Articles (100)
Healthcare stocks with strong revenue growth and attractive valuations
BHC Q3 Earnings Preview: Here's What You Should Know
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
4 Small-Cap Stocks With Paths to Recovery After the Fed's September Rate Hike
Harmony Biosciences drops amid court hearing on Wakix patent
HRMY or ARGX: Which Is the Better Value Stock Right Now?
Centene, Harmony Biosciences lead list of undervalued healthcare stocks
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Harmony Biosciences Holdings, Inc. $HRMY Shares Purchased by CWA Asset Management Group LLC
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Why Harmony Biosciences Stock Got Mashed on Monday
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down – What’s Next?
Harmony Biosciences appoints Peter Anastasiou as CEO
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Insider Selling: Harmony Biosciences (NASDAQ:HRMY) Insider Sells $34,400.00 in Stock
Kumar Budur Sells 1,800 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock
Undervalued healthcare stocks with attractive valuation grades
Ten healthcare stocks with A-rated valuations and strong revenue growth
Legal & General Group Plc Invests $3.50 Million in Harmony Biosciences Holdings, Inc. $HRMY
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Bank of New York Mellon Corp Buys Shares of 272,926 Harmony Biosciences Holdings, Inc. $HRMY
Canada Pension Plan Investment Board Takes $1.21 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Holdings, Inc. $HRMY Position Raised by California State Teachers Retirement System
Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
Zacks.com featured highlights TD SYNNEX, Ameriprise, Harmony and Newell Brands
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
4 Stocks Trading Near 52-Week High With More Upside Potential
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
NVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 Growth
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
ZTS Set to Report Q2 Earnings: Here's What Investors Should Expect
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
Dimensional Fund Advisors LP Buys 245,784 Shares of Harmony Biosciences Holdings, Inc. $HRMY
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
4 Value Stocks to Buy as Fed Holds Rates, Mideast Risks Rise
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
BMY Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
HRMY or ACAD: Which Is the Better Value Stock Right Now?
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline
Zacks.com featured highlights include Harmony Biosciences, Invesco, General Motors, Hewlett Packard and Quanex Building
5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfolio
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
Zacks Value Investor Highlights: HRMY, NVDA and VLO
How Many Stocks Should You Own?
EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
Zacks.com featured highlights Harmony, StoneCo, General Motors, Hewlett and Nexa
HRMY vs. AMGN: Which Stock Is the Better Value Option?